Compare CVS & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVS | SNY |
|---|---|---|
| Founded | 1963 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.7B | 119.4B |
| IPO Year | N/A | N/A |
| Metric | CVS | SNY |
|---|---|---|
| Price | $78.15 | $46.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 6 |
| Target Price | ★ $94.33 | $61.50 |
| AVG Volume (30 Days) | ★ 11.1M | 4.7M |
| Earning Date | 02-10-2026 | 01-29-2026 |
| Dividend Yield | 3.39% | ★ 3.48% |
| EPS Growth | N/A | ★ 44.16 |
| EPS | 1.39 | ★ 7.52 |
| Revenue | ★ $399,834,000,000.00 | $54,850,299,422.00 |
| Revenue This Year | $3.67 | $2.70 |
| Revenue Next Year | $5.38 | $6.84 |
| P/E Ratio | $56.46 | ★ $12.14 |
| Revenue Growth | ★ 7.87 | 5.49 |
| 52 Week Low | $58.35 | $44.62 |
| 52 Week High | $85.15 | $60.12 |
| Indicator | CVS | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 52.91 | 44.94 |
| Support Level | $73.00 | $47.39 |
| Resistance Level | $78.96 | $49.42 |
| Average True Range (ATR) | 2.75 | 0.74 |
| MACD | 0.22 | 0.08 |
| Stochastic Oscillator | 96.67 | 31.32 |
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.